Long acting insulin - Gan & Lee Pharmaceuticals

Alternative Names: GZR-4; Long acting insulin analog - Gan & Lee Pharmaceuticals

Latest Information Update: 16 Oct 2024

Price : $50 ^*

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Gan&Lee Pharmaceuticals
Class Antihyperglycaemics; Hepatoprotectants; Insulins; Pancreatic hormones
Mechanism of Action Ornithine decarboxylase stimulants; Phosphokinase stimulants; Protein tyrosine kinase stimulants

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

15 Oct 2024 Efficacy and adverse events data from a phase II trial in Type 2 diabetes mellitus released by Gan&Lee Pharmaceuticals
14 Sep 2024 Pharmacodynamics, pharmacokinetics and adverse events data from a phase Ia trial In volunteers released by Gan & Lee Pharmaceuticals
14 Sep 2024 Pharmacodynamics, pharmacokinetics and adverse events data from a phase Ib trial Type 2 diabetes mellitus released by Gan & Lee Pharmaceuticals

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com